{
    "code": 0,
    "data": [
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Attached",
            "news_id": "0876bbd9-53e8-4347-9b36-c52766a98c13",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=49771ba0-e85e-4a5e-874e-143583c5be01.pdf",
            "news_date": "2026-02-03 16:19:51",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Attached",
            "news_id": "291485d5-b3aa-4fb0-a92d-48ab7b1a780e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a727d4d4-3877-427b-aef9-e6796c657495.pdf",
            "news_date": "2026-01-30 13:40:39",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Nine Months Ended December 31 2025",
            "news_body": "Attached",
            "news_id": "029fbb20-7165-4dd3-817f-afe48c704bcb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=327e0937-73e7-46a0-bc24-368cdbb99188.pdf",
            "news_date": "2026-01-30 13:18:41",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Nine Months Ended December 31 2025",
            "news_body": "Attached",
            "news_id": "265b8eb9-795f-4590-8f81-7fd1ca55b973",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ebb7962e-1797-4fa7-9d96-813069a83706.pdf",
            "news_date": "2026-01-30 13:17:41",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Attached",
            "news_id": "68331deb-9fa9-4a30-b7c8-675af9ce69bc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=72aaf1b0-aee8-4662-80c6-b79ce815de67.pdf",
            "news_date": "2025-11-06 17:42:16",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Attached",
            "news_id": "32a13981-fdee-4e97-9e29-4966ea7b6b3c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=101cf07b-53bf-462b-a262-f90744460d59.pdf",
            "news_date": "2025-10-31 14:28:48",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Half Year Ended September 30 2025",
            "news_body": "Attached",
            "news_id": "934024fd-59c1-4a85-b41c-83478d40ed62",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ba922db2-3a5b-4958-b0c9-e899fee99551.pdf",
            "news_date": "2025-10-31 14:11:06",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Attached",
            "news_id": "e3e53d9c-5d21-4434-bf22-0cdbc8b0a360",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=29dc0db7-9534-4808-9188-fa0967de5858.pdf",
            "news_date": "2025-08-05 18:14:56",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earnings presentation on the Un-audited Financial Results for the quarter ended June 30 2025",
            "news_id": "2da50a24-2dcf-4760-9023-9fa316bbcb2c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8834879a-7f92-41e5-b45b-cf0dfbbe29b0.pdf",
            "news_date": "2025-07-31 13:49:32",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results- Financial Results For The Quarter Ended June 30 2025",
            "news_body": "Attached",
            "news_id": "f51d3779-0b61-4f5d-a9d5-6c3fc3efafad",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e31979a-b805-405c-bede-fde858625edf.pdf",
            "news_date": "2025-07-31 13:25:58",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Attached",
            "news_id": "fad4f710-634d-4410-99d2-0098e2fe0238",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e38753cd-4a30-4315-b703-f0b70866faf5.pdf",
            "news_date": "2025-05-01 17:02:42",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earnings Presentation on Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31 2025",
            "news_id": "6e68fd4d-ef4c-46ae-b736-1c48e1e084a4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cc1efdd-78b8-43a8-8804-244cfc224cc0.pdf",
            "news_date": "2025-04-25 15:02:13",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Financial Year Ended March 31 2025",
            "news_body": "Attached",
            "news_id": "705a7eb0-755f-41de-8a47-d2a3d76215c0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=16d95e8c-570f-4d77-ade5-f7a52c58f63e.pdf",
            "news_date": "2025-04-25 14:20:33",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Attached",
            "news_id": "81fea7cd-35f4-4c1c-b938-cfa8869c1a97",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1c37cb06-7fc7-4037-8ef2-4b1f5aa51ce5.pdf",
            "news_date": "2025-02-03 17:59:45",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earnings presentation on Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31 2024",
            "news_id": "7f08ee44-cd29-4398-b1d6-11d3c15821b5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f8142dc-63a3-4c39-ba57-83394a241be3.pdf",
            "news_date": "2025-01-30 14:12:58",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Nine Months Ended December 31 2024",
            "news_body": "Attached",
            "news_id": "681b6d3d-ec08-4744-b69e-380766a21b47",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7c26f96d-9a9c-4ff1-ad67-ead0d63893db.pdf",
            "news_date": "2025-01-30 13:39:15",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript for Q2 & H1 FY25 is attached",
            "news_id": "204c323b-1624-478b-9d6a-b04e3e0d5e96",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e8e67b58-df7c-4fd4-810e-72f8a80eb900.pdf",
            "news_date": "2024-10-28 16:18:44",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investors Presentation for the period ended September 30, 2024",
            "news_id": "c8ad4bad-05be-486f-ab78-92d81c86b6d7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a7b8bed5-ea31-4c19-87b5-d8c9a385eb6d.pdf",
            "news_date": "2024-10-23 15:59:44",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For The Period Ended September 30, 2024",
            "news_body": "Attached",
            "news_id": "e867f73b-3e04-4e2b-8c30-6294d99924e1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=89ed1f5c-08c9-4005-89c3-0ad10f206af6.pdf",
            "news_date": "2024-10-23 15:38:32",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript for Q1 FY25",
            "news_id": "3fdde415-a97e-44d4-ae67-6e5305c608d0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3bd14b0-3e94-4070-888a-c701d5880c9a.pdf",
            "news_date": "2024-08-13 08:52:32",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording of Earnings Conference Call with Investors/ Analysts for Q1 FY25",
            "news_id": "5a5cd062-20f8-47ee-86ec-27c8c27ef72e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=59773200-7df8-4ed5-a72a-2e6fd5692146.pdf",
            "news_date": "2024-08-07 20:20:20",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earnings presentations on unaudited financial results for quarter ended June 30, 2024",
            "news_id": "da95d5b4-bd74-4c2d-bea2-503f666e2fb1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ff0941dc-c229-4de0-a70f-c13faccb28c9.pdf",
            "news_date": "2024-08-07 15:40:01",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For Quarter Ended June 30, 2024",
            "news_body": "Results for quarter ended June 30, 2024",
            "news_id": "cf06232f-7539-4451-b1a0-f9cecf64d223",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca9d4740-7af2-4cb4-84a6-652c458dc940.pdf",
            "news_date": "2024-08-07 15:08:58",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for Q4 & FY 24 attached",
            "news_id": "f6e39466-8209-4fcc-9c84-3ae982c831b3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=22b6e849-f295-4719-a130-4142d3fbd557.pdf",
            "news_date": "2024-05-20 13:24:36",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Q4 & F.Y. 2024 Earnings Call Transcript is attached",
            "news_id": "2f44d148-a670-405c-bb36-97cfb9fe15e6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2c54fcb7-0e48-49a6-ac84-367aa98ffd01.pdf",
            "news_date": "2024-05-15 19:45:59",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Revised Earnings presentation on Audited financial results for Q4 and financial year ended March 31, 2024",
            "news_id": "daacabc2-73e4-491d-9f8a-72d88a7ab7d0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7bcbea66-e181-4a5e-b5cd-ecc762c2c9fc.pdf",
            "news_date": "2024-05-10 15:01:53",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earnings presentation on Audited Financial Results (Standalone & Consolidated) for Q4 and FY ended March 31, 2024",
            "news_id": "f906948d-c75b-409c-b93b-e361d1458cd0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34b1d4bf-fc61-4547-842c-e7423f8f9fe9.pdf",
            "news_date": "2024-05-10 14:12:31",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For Q4 And FY Ended March 31, 2024",
            "news_body": "Attached",
            "news_id": "b3921284-816a-42da-81ab-99020e3a19ab",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3b04ec5-bf50-4a80-bbdb-4b5b0b02143c.pdf",
            "news_date": "2024-05-10 13:40:48",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of conference call on Financial Results for Q3 & 9M FY 24",
            "news_id": "63d709bf-9bd1-4ff5-9f4c-35104c34facb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=44a76bd5-05a2-4a29-834a-ecaf1280f47d.pdf",
            "news_date": "2024-02-07 15:52:27",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Earnings Conference Call dated February 01, 2024 with Investors/ Analysts for Q3 & 9M FY24 is available on the Company's website at https://www.lalpathlabs.com/investors/investors-inside/quarterly-result",
            "news_id": "60c98962-d0bb-478b-ad19-e0612108b380",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=07ae3308-8e46-4a77-9154-f81ec366d1c9.pdf",
            "news_date": "2024-02-01 18:56:08",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation on Q3 & 9M FY 24 Financial Results",
            "news_id": "3dbb5079-0a2f-4623-9d83-bee731355308",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a77d6b9c-0596-4975-87e4-9e44ba7582f0.pdf",
            "news_date": "2024-02-01 14:08:27",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Nine Months Ended December 31, 2023",
            "news_body": "Financial Results for the quarter and nine months ended December 31, 2023",
            "news_id": "131b5a29-776a-4d74-887a-3e034daa43cb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bdf7f067-3524-446b-af3a-2f116b030ab8.pdf",
            "news_date": "2024-02-01 13:30:10",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earning call transcript for Q2 H1 FY24",
            "news_id": "a9c74f7a-9555-4a1f-bc43-8c39eff1b945",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=220eb50a-c82a-48b5-b6eb-f62e376573c0.pdf",
            "news_date": "2023-11-08 16:09:10",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Conference Call dated November 02, 2023 with Investors/ Analysts for Q2 & H1 FY24 is available on the Company's website",
            "news_id": "7000637d-77b8-4a7f-9bcf-05f0d94cb89d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e25851b0-cef4-4182-97f8-7706c3ff95e0.pdf",
            "news_date": "2023-11-02 18:47:48",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earning Presentation for the Q2 & H1 FY 24",
            "news_id": "933e883f-59d9-4f70-8ce6-d4301defbde0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2c675f3-8b1c-4538-b0d7-ba066ab36542.pdf",
            "news_date": "2023-11-02 13:50:29",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Half Year Ended September 30, 2023",
            "news_body": "Financial Results for the Quarter and Half Year ended September 30, 2023",
            "news_id": "a02a5d1b-0bb0-47ab-b5db-ab0e15ce7a80",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87803b7b-3c98-4e21-8e9c-0427035b33f8.pdf",
            "news_date": "2023-11-02 13:37:48",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Intimation regarding Corporate Presentation for Q1 FY24",
            "news_id": "eb5f48e1-bfba-4678-8db1-5031d7cfeadf",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=06ee4950-691a-43af-b63a-c9b3ba2315a0.pdf",
            "news_date": "2023-08-08 16:15:36",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of conference call on Financial Results for Q1 FY24",
            "news_id": "c41844e8-f5a9-4d60-b709-764b6a11fddb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f1766a4c-153c-4afb-a2ad-1a1a3b8d0eb9.pdf",
            "news_date": "2023-08-02 10:20:33",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Conference Call dated July 27, 2023 with Investors/ Analysts for Q1 FY24 is available on the Company's website at https://www.lalpathlabs.com/investors/investors-inside/quarterly-result",
            "news_id": "533eeb07-1994-4c02-8787-28825a80324d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1306635d-2887-4995-8067-92b1713f10eb.pdf",
            "news_date": "2023-07-27 19:10:37",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation with regard to Un-Audited Financial Results for the quarter ended June 30, 2023",
            "news_id": "2788449d-a2d8-4f17-9921-a415812f5396",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbe792ef-c5cd-4673-b079-aaa5058b4474.pdf",
            "news_date": "2023-07-27 15:01:14",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For The Quarter Ended June 30, 2023",
            "news_body": "Un-Audited Financial Results for the quarter ended June 30, 2023",
            "news_id": "3ec06b2f-c282-46cc-bff2-8b65cdb9b86d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=11323c0f-b0fd-4ba2-847e-f07cf93f37d2.pdf",
            "news_date": "2023-07-27 14:28:21",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Transcript of Conference Call on Financial Results for Q4 & FY23.",
            "news_id": "3bc5ca66-12f1-48b6-811b-075cdc5c4212",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2acc3ce5-b27e-40a6-83a0-c5267c3fa1da.pdf",
            "news_date": "2023-05-16 20:03:01",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Conference Call dated May 11, 2023 with Investors/ Analysts for Q4 & FY23 is available on the Company's website at https://www.lalpathlabs.com/investors/investors-inside/quarterly-result",
            "news_id": "240d87cb-841f-485e-aae3-46c4e3832b56",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2981d532-a9ac-48fe-a7fa-a83a8b433378.pdf",
            "news_date": "2023-05-11 21:28:02",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached a copy of Company''s Q4 & FY23 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2023, as approved by the Board of Directors in their meeting held on May 11, 2023.",
            "news_id": "03d0da25-399b-4d3b-bc89-74c7f5f8d010",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0bc2fb57-f2d0-4a25-895f-4806f0cb8929.pdf",
            "news_date": "2023-05-11 14:29:09",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Financial Year Ended March 31, 2023",
            "news_body": "Please take note that the Board of Directors in their meeting held today i.e. May 11, 2023 inter-alia considered and approved the Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Financial Year ended March 31, 2023.",
            "news_id": "0d0d6c7a-8bdb-4c96-bb92-c5b39bb3fc21",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8160c643-6929-4d31-8d76-6b3265bec2af.pdf",
            "news_date": "2023-05-11 14:04:00",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Financial Results Conference Call Transcript of the Company for Q3 FY23.",
            "news_id": "7e563749-979d-4479-a95a-23bd80c2f4d3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f49f6aaf-f516-46a3-91fa-985bae22f0da.pdf",
            "news_date": "2023-02-08 16:12:58",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Conference Call dated February 02, 2023 with Investors/ Analysts for Q3 & 9M - FY23 is available on the Company's website at https://www.lalpathlabs.com/investors/investors-inside/quarterly-result",
            "news_id": "9f0f69a5-b4ab-4c26-b2d3-4a5705782b9b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=79a498d3-eb94-4336-840d-9a3954dc8cd8.pdf",
            "news_date": "2023-02-02 20:00:36",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached a copy of Company''s Q3 & 9M FY23 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2022, approved by the Board of Directors in their meeting held on February 02, 2023.",
            "news_id": "c3227155-16d8-40be-909a-cb64531029ae",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f4f5f5f0-5337-4c04-8e3a-0538eaca1147.pdf",
            "news_date": "2023-02-02 14:30:55",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On February 02, 2023",
            "news_body": "Please take note that the Board of Directors in their meeting held today i.e. February 02, 2023 approved the following item(s):<BR> <BR> 1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine months ended December 31, 2022.<BR> <BR> A copy of the above Financial Results along with Limited Review Reports thereon issued by the Statutory Auditors, M/s Deloitte Haskins & Sells, LLP for the Quarter and Nine months ended December 31, 2022 are attached herewith as an Annexure- A.<BR> <BR> 2. Appointment of Mr. Arun Duggal (DIN: 00024262) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from February 02, 2023 subject to approval of Shareholders of the Company through postal ballot process.   <BR>",
            "news_id": "038a1b08-e11e-4e4e-a22e-2ab0231cfc3a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0336bd49-3a78-41a8-b7ea-3600176cc8ce.pdf",
            "news_date": "2023-02-02 14:16:53",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For Quarter And Nine Months Ended December 31, 2022",
            "news_body": "Please take note that the Board of Directors in their meeting held today i.e. February 02, 2023 approved the following item(s):<BR> 1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine months ended December 31, 2022.<BR> A copy of the above Financial Results along with Limited Review Reports thereon issued by the Statutory Auditors, M/s Deloitte Haskins & Sells, LLP for the Quarter and Nine months ended December 31, 2022 are attached herewith as an Annexure- A.<BR> 2. Appointment of Mr. Arun Duggal (DIN: 00024262) as an Additional Director in the category of Independent Director of the Company for a term of three (3) years commencing from February 02, 2023 subject to approval of Shareholders of the Company through postal ballot process.<BR> <BR> The Board Meeting commenced at 11:00 A.M and concluded at 02:00 P.M.",
            "news_id": "0a6a8e18-c7a2-41ea-a54a-935b6b0bbb7f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a12da61-b344-4ddc-93cf-97332ac1e0dc.pdf",
            "news_date": "2023-02-02 14:13:03",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Financial Results Conference Call Transcript of the Company for Q2 & H1 FY23.",
            "news_id": "a0638605-4c9e-493e-9820-b1c15e9df9f1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b7dbd2cd-51b7-41a8-adbe-48db00e721fa.pdf",
            "news_date": "2022-11-14 16:59:16",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Conference Call dated November 08, 2022 with Investors/ Analysts for Q2 & H1 - FY23 is available on the Company's website at https://www.lalpathlabs.com/investors/investors-inside/quarterly-result We request you to kindly take the same on record.",
            "news_id": "2316900e-149e-457b-9cb4-8656d9be37d5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d5a025e-4a76-4750-a01c-b1ba2dd44fa4.pdf",
            "news_date": "2022-11-08 19:48:36",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached a copy of Company''s Q2 & H1 FY23 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2022, approved by the Board of Directors in their meeting held on November 08, 2022.",
            "news_id": "34b0a6ee-d7e0-4681-a2d2-264b69984951",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3f57d454-041a-4e25-b8e2-fa129766388a.pdf",
            "news_date": "2022-11-08 14:38:35",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On November 11, 2022",
            "news_body": "Please take note that the Board of Directors in their meeting held today i.e. November 08, 2022<BR> approved the following item(s):<BR> 1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the<BR> Quarter and Half Year ended September 30, 2022.<BR> A copy of the above Financial Results along with Limited Review Reports thereon issued by<BR> the Statutory Auditors, M/s Deloitte Haskins & Sells, LLP for the Quarter and Half Year<BR> ended September 30, 2022 are attached herewith as an Annexure- A.<BR> 2. Appointment of Mr. Rohit Bhasin (DIN: 02478962) as an Additional Director in the category<BR> of Independent Director of the Company for a term of three (3) years commencing from<BR> November 08, 2022 subject to approval of Shareholders of the Company through postal<BR> ballot process.<BR> Please also take note that Mr. Rohit Bhasin is not debarred from holding the office of<BR> Director by virtue of any order of Securities and Exchange Board of India or any other such<BR> Authority.",
            "news_id": "bae10e6d-1770-489a-b2c7-d8ddcc531d5e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=436cc895-ad99-48ca-8107-ea4d90356036.pdf",
            "news_date": "2022-11-08 14:16:31",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results:Un-Audited Financial Results For Quarter And Half Year Ended September 30, 2022",
            "news_body": "Please take note that the Board of Directors in their meeting held today i.e. November 08, 2022 approved the following item(s):<BR> 1. Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Half Year ended September 30, 2022.<BR> A copy of the above Financial Results along with Limited Review Reports thereon issued by the Statutory Auditors, M/s Deloitte Haskins & Sells, LLP for the Quarter and Half Year<BR> ended September 30, 2022 are attached herewith as an Annexure- A.<BR> 2. Appointment of Mr. Rohit Bhasin (DIN: 02478962) as an Additional Director in the category<BR> of Independent Director of the Company for a term of three (3) years commencing from<BR> November 08, 2022 subject to approval of Shareholders of the Company through postal<BR> ballot process.<BR> Please also take note that Mr. Rohit Bhasin is not debarred from holding the office of Director by virtue of any order of Securities and Exchange Board of India or any other such<BR> Authority.",
            "news_id": "bcc7b126-0d01-40d7-bb4d-dfaf4ce5866b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5902cb29-88e5-4026-be81-a8d2d9b66ca5.pdf",
            "news_date": "2022-11-08 14:12:38",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Financial Results Conference Call Transcript of the Company for Q1 FY23.",
            "news_id": "c14a12fe-47be-446e-a143-688ba99c62c1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=105d8fd2-2a6a-4e04-a818-a56e4adb6c4f.pdf",
            "news_date": "2022-08-03 16:47:04",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached a copy of Company''s Q1 FY23 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Unaudited FinancialResults (Standalone and Consolidated) for the Quarter ended June 30, 2022, approved by the Board of Directors in their meeting held on July 28, 2022.",
            "news_id": "ecdef5c7-763d-4bd1-82d7-77ca893e1a27",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d91ea135-baa5-4ae3-a22c-c93d6040f7ab.pdf",
            "news_date": "2022-07-28 14:07:52",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For First Quarter Ended June 30, 2022",
            "news_body": "The Board Meeting commenced at 11.00 A.M. and the item related to the Financial Results for the first quarter ended June 30, 2022 was approved by the Board at 1:00 P.M. The Board Meeting is still continuing for discussing other Agenda Item(s).<BR> <BR> We request you to please take the same on record. <BR>",
            "news_id": "4e3000a5-83d3-4a7f-9123-150fa8104a8f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0502a24f-bcc8-4813-bbc0-f7c65e158aa4.pdf",
            "news_date": "2022-07-28 13:14:05",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On July 28, 2022",
            "news_body": "Please take note that the Board of Directors in their meeting held today i.e. July 28, 2022 approved Unaudited Financial Results (Standalone and Consolidated) of the Company for the first quarter ended June 30, 2022.<BR> <BR> A copy of the Results along with Limited Review Report issued by the Statutory Auditors                 M/s Deloitte Haskins & Sells, LLP on such financials for the first quarter ended June 30, 2022 is attached herewith.<BR> <BR> At the said Meeting, the Board of Directors have also declared an interim dividend of Rs. 6/-per equity share (i.e. 60% on a face value of Rs. 10/- per share) for the FY 2022- 23. <BR> <BR> The Board Meeting commenced at 11.00 A.M. and the item related to the Financial Results for the first quarter ended June 30, 2022 was approved by the Board at 1:00 P.M. The Board Meeting is still continuing for discussing other Agenda Item(s).<BR> <BR> We request you to please take the same on record.<BR>",
            "news_id": "e45ffe81-450d-4868-ab50-f9980bd464c4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0b50126d-7aa3-42e5-9a9a-60f428950b21.pdf",
            "news_date": "2022-07-28 13:09:06",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Financial Results Conference Call Transcript of the Company for Q4 FY22. We request you to please take the same on record.",
            "news_id": "40c0bb05-df0b-4211-af20-675b0eeaaf1d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cec6cf62-e664-42f6-8786-bf9a1194759e.pdf",
            "news_date": "2022-05-23 14:56:10",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), please find attached herewith Corporate Presentation of the Company for Q4 & FY22, which the Company proposes to share with analysts/ investors.We request you to please take the same on record.",
            "news_id": "91e0d12d-f828-4cfe-9c34-e83485ce5711",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3a9d9b46-2293-41e3-9ad1-be2b1155291a.pdf",
            "news_date": "2022-05-23 11:13:07",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that the audio recording of the Company's Conference Call dated May 17, 2022 with Investors/ Analysts for Q4 & FY22 is available on the Company's website at https://www.lalpathlabs.com/investor/quarterly-results.aspx We request you to kindly take the same on record.",
            "news_id": "4972b02c-8c2d-4fa0-a46d-e6b5df670cfc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=32f93a10-f5e3-4933-b3b3-c7a36e89d573.pdf",
            "news_date": "2022-05-17 21:14:23",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations), please find attached herewith CorporatePresentation of the Company for Q4 & FY22, which the Company proposes to share with analysts/ investors.We request you to please take the same on record.",
            "news_id": "6ef77e48-5e5c-4180-abeb-a058c084abf7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4d9fe27d-b86c-423f-ac05-9921f6d59f4a.pdf",
            "news_date": "2022-05-17 16:19:55",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On May 17, 2022",
            "news_body": "The Audited Standalone and Consolidated Financial Results ('Results') of the Company for the Quarter and Financial Year ended March 31, 2022. A copy of the signed Results along with Auditors Report and Declaration in respect of Audit Report with unmodified opinion under Regulation 33 of the Listing Regulations is attached herewith.",
            "news_id": "4ee02306-11b8-4bc2-9aee-e2992c3d8313",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5411426d-4ea9-4256-b491-19ff99120a3d.pdf",
            "news_date": "2022-05-17 15:49:19",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On May 17, 2022",
            "news_body": "Please take note that the Board of Directors in their meeting held today i.e. May 17, 2022 approved following matters:<BR> <BR> 1. The Audited Standalone and Consolidated Financial Results ('Results') of the Company for the Quarter and Financial Year ended March 31, 2022. A copy of the signed Results along with Auditors Report and Declaration in respect of Audit Report with unmodified opinion under Regulation 33 of the Listing Regulations is attached herewith as Annexure-A.<BR>",
            "news_id": "f27ff5d4-82f7-4bb3-95ee-7cbd53d5745a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c75882f-4d05-43dd-a9e4-572feeff2aca.pdf",
            "news_date": "2022-05-17 15:46:39",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Financial Results Conference Call Transcript of the Company for Q3 FY22. We request you to please take the same on record.",
            "news_id": "26af3256-9745-49aa-85e6-b60bcd82e2ba",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f5e3da5-05e4-4b52-98a5-c372593eabd3.pdf",
            "news_date": "2022-02-25 13:22:25",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached a copy of Company''s Q3 & 9M FY22 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2021, approved by the Board of Directors in their meeting held on February 10, 2022.",
            "news_id": "abd4f588-e171-49a1-9a75-b09739a4fbe2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0a789206-d216-497a-b241-eda223446cb2.pdf",
            "news_date": "2022-02-10 15:22:28",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On February 10, 2022",
            "news_body": "Please take note that the Board of Directors in their meeting held today i.e. February 10, 2022 approved Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine Months ended December 31, 2021.<BR> <BR> A copy of the signed Results along with Limited Review Report issued by the Statutory Auditors    M/s Deloitte Haskins & Sells, LLP on such financials for the Quarter and Nine Months ended December 31, 2021 is attached herewith.<BR> <BR> The Board Meeting commenced at 11:00 A.M. and concluded at 2:30 P.M.<BR>",
            "news_id": "46421a87-336e-4473-be2d-fbf5527a170b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a32007f1-19e4-423b-9a3f-53b2277d6c78.pdf",
            "news_date": "2022-02-10 14:56:50",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results- Financial Results For The Quarter And Nine Months Ended December 31, 2021",
            "news_body": "Please take note that the Board of Directors in their meeting held today i.e. February 10, 2022 approved Un-audited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine Months ended December 31, 2021.<BR> <BR> A copy of the signed Results along with Limited Review Report issued by the Statutory Auditors    M/s Deloitte Haskins & Sells, LLP on such financials for the Quarter and Nine Months ended December 31, 2021 is attached herewith.<BR> <BR> The Board Meeting commenced at 11:00 A.M. and concluded at 2:30 P.M.",
            "news_id": "6e762226-1d99-4d99-a869-132e8e465bd0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3dc8472f-cd0f-4235-a36f-fbc841f9f26f.pdf",
            "news_date": "2022-02-10 14:53:23",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Financial Results Conference Call Transcript of the Company for Q2 FY22. <BR> <BR> We request you to please take the same on record.<BR>",
            "news_id": "6793c01c-dd83-4ea6-96cc-a4175a4559b2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e19bfc39-43e6-45b1-add1-9e49fdacc488.pdf",
            "news_date": "2021-11-15 13:09:26",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached herewith a copy of Company''s Q2, H1 FY22 Earnings Presentation, which the Company proposes to share with Analysts I Investors with respect to its Unaudited<BR> Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2021 , approved by the Board of Directors in their meeting held on October 26, 2021.<BR> We request you to please take the same on record.",
            "news_id": "05b7374e-d573-4577-a2e7-5ef23028cda5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab98557e-1ccc-47d4-ba56-0d743d01d66c.pdf",
            "news_date": "2021-10-26 20:40:53",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results- Financial Results For The Quarter And Half Year Ended September 30, 2021",
            "news_body": "Please take note that the Board of Directors in its meeting held today i.e. October 26, 2021<BR> approved the following items:<BR> 1. Unaudited Financial Results (Standalone and Consolidated} of the Company for the<BR> Quarter and Half Year ended September 30, 2021.<BR> A copy of the Results along with Limited Review Report issued by the Statutory  <BR> Auditors, M/s Deloitte Haskins & Sells, LLP, on such financials for the Quarter and<BR> Half Year ended September 30, 2021 is attached herewith.<BR> The Board Meeting commenced at 13:30 P.M and concluded at 16:30 P.M.",
            "news_id": "99dd17f4-43db-4ba0-aa22-a1b56aaad439",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d433bd0a-7981-40c8-83a7-2ea4d4813f12.pdf",
            "news_date": "2021-10-26 16:51:15",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Please take note that the Board of Directors in its meeting held today i.e. October 26, 2021<BR> approved the following items:<BR> 1. Unaudited Financial Results (Standalone and Consolidated} of the Company for the Quarter and Half Year ended September 30, 2021.<BR> A copy of the Results along with Limited Review Report issued by the Statutory<BR> Auditors, M/s Deloitte Haskins & Sells, LLP, on such financials for the Quarter and<BR> Half Year ended September 30, 2021 is attached herewith.<BR> 2. (a} Re-appointing (Hony) Brig. Dr. Arvind Lal (DIN: 00576638) as Executive Chairman and Whole Time Director for a period of five (5) years, commencing from April 1, 2022.<BR> (b} Re-appointing Mrs. Somya Satsangi (DIN: 07275574) as Independent Director for another term of 5 consecutive years, commencing from February 8, 2022 <BR> The Board Meeting commenced at  13:30 P.M and concluded at 16:30 P.M.",
            "news_id": "03901332-e1c5-45ca-9cd5-ddbfccee9dee",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3de80890-62f1-4833-97d2-28cf47bcfa91.pdf",
            "news_date": "2021-10-26 16:47:17",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Financial Results Conference Call<BR> Transcript of the Company for Q1 FY22",
            "news_id": "3063ecfa-4443-4469-b249-5efc2a239365",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dff2a51d-f34d-4b1b-b5e2-b8450beb9211.pdf",
            "news_date": "2021-08-11 10:08:24",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Earnings Presentation on Unaudited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2021",
            "news_id": "7f7f01d7-e104-4a59-84f6-0cd83c6d449d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1863e583-da92-488c-8b66-87c187a5def2.pdf",
            "news_date": "2021-07-30 13:32:35",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On July 30, 2021",
            "news_body": "Please take note that the Board of Directors in their meeting held today i.e. July 30, 2021<BR> approved Unaudited Financial Results (Standalone and Consolidated) of the Company for the<BR> Quarter ended June 30, 2021.   <BR> A copy of the Results along with Limited Review Report issued by the Statutory Auditors<BR> M/s Deloitte Haskins & Sells, LLP on such financials for the Quarter ended June 30, 2021 is<BR> attached herewith.<BR> At the said Meeting, the Board of Directors have also declared an interim dividend of Rs. 6/-<BR> per equity share (i.e. 60% on a face value of Rs. 10/- per share) for the Financial Year<BR> 2021- 22.<BR> Also, kindly take note that the Board has fixed August 22, 2021 as the record date for the<BR> purpose of payment of interim dividend. The interim dividend will be paid by the Company on<BR> or before August 28, 2021.<BR> The Board Meeting commenced at 10.30 A.M. and concluded at 1:10 P.M.",
            "news_id": "0cc6e86d-cef7-4823-b1e1-dea2e4122753",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea0335b3-8f61-4607-8531-e97fc726a474.pdf",
            "news_date": "2021-07-30 13:22:24",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith Financial Results Conference Call Transcript of the Company for Q4 & FY21",
            "news_id": "e6b06c6e-9b10-45b3-8d3d-107203b736b7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f921f9b-41d4-4a12-b77e-3c6d7bb865cc.pdf",
            "news_date": "2021-06-08 16:28:34",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulations), please find attached herewith Corporate Presentation of the Company for Q4 & FY 21, which the Company proposes to share with analysts/investors.<BR> We request you to please take the same on record.",
            "news_id": "0e724cfe-89d2-4653-86fa-75ff57973d36",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d4e3e8c-ee0b-43ce-b001-d0664d3d6d3d.pdf",
            "news_date": "2021-05-24 14:29:18",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached herewith a copy of Company''s Q4/ FY 2021 Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Audited<BR> Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2021.",
            "news_id": "a8257ead-eb50-407d-a873-17b451f350ef",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a47880e-e4f6-4502-a94a-488371e86530.pdf",
            "news_date": "2021-05-21 16:03:55",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "LALPATHLAB",
            "disp": "Dr. Lal Path Labs",
            "bse_code": 539524,
            "isin": "INE600L01024",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On May 21, 2021",
            "news_body": "1. The Audited Standalone and Consolidated Financial Results ('Results') of the Company<BR> for the Quarter and Financial Year ended March 31, 2021. A copy of the signed Results<BR> along with Auditors Report and Declaration in respect of Audit Report with unmodified<BR> opinion under Regulation 33 of the Listing Regulations is attached herewith.<BR> 2. Convening of 27th Annual General Meeting (AGM) of the Company on Thursday July 29,<BR> 2021 through Video Conferencing/Other Audio Visual Means (VC/OVAM).<BR> 3. Recommendation of final dividend of Rs. 8 /- per equity share (@ 80 % on a face value of<BR> Rs. 10/- per share) for the year ended March 31, 2021. The dividend, if approved by the<BR> shareholders at the ensuing Annual General Meeting (AGM) will be dispatched/ credited<BR> within 30 days of the AGM.<BR> 4. Pursuant to Regulation 42 of Listing Regulations, the Board has fixed July 22, 2021 as the<BR> Record Date for the purpose of payment of Final Dividend for Financial Year 2020-21 (if<BR> approved by the Shareholders).<BR>",
            "news_id": "286c98f2-8b4d-4bd1-9cc1-ac7ba57a6b55",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6224d127-1de6-4c24-97d6-93b7438f28c8.pdf",
            "news_date": "2021-05-21 15:46:51",
            "seo": "dr-lal-pathlabs-ltd",
            "ltp": 1443.8,
            "ch": -12,
            "pch": -0.8242890506937767,
            "inst": "EQUITY",
            "ts": 0.1,
            "ls": 1,
            "mtp": 1,
            "sid": 11654,
            "exch": "NSE",
            "seg": "E"
        }
    ],
    "remarks": ""
}